Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinsons disease brains
Many individuals seeking obesity treatment also exhibit BED of low frequency and/or limited duration (Dalle Grave, 2023)
Clinical trials show tirzepatide produces 22.5% average weight loss compared to semaglutides 14.9%, likely because activating both incretin pathways provides more comprehensive metabolic regulation than activating one pathway alone
Of these trials, four compared DPP-4 inhibitors against placebo (SAVOR-TIMI 53, EXAMINE, TECOS, CARMELINA), eight compared GLP-1RA against placebo (ELIXA, LEADER, SUSTAIN-6, EXSCEL, HARMONY, REWIND, PIONEER 6, AMPLITUTE-O) and eleven compared SGLT-2 inhibitors against placebo (EMPA-REG, CANVAS, DECLARE, CREDENCE, DAPA-HF, DAPA CKD, VERTIS-CV, EMPEROR-R, SCORED, SOLOIST-WHF, EMPEROR-P)
Comparing GLP-1 Medications: Key Differences and Considerations Choosing among the various GLP 1 options requires understanding key differences in dosing frequency, efficacy and practical considerations around cost and access
Down 38 pounds and counting!" *Results not typical
